/
To  Pump  OR   To Inject To  Pump  OR   To Inject

To Pump OR To Inject - PowerPoint Presentation

pasty-toler
pasty-toler . @pasty-toler
Follow
361 views
Uploaded On 2018-03-15

To Pump OR To Inject - PPT Presentation

t hat is the Question Sanoe Harrison amp Patrick Hanley Autoimmune Diabetes Mellitus Review of Problem Glucose in Healthy Volunteers Day Ave SD 930 70 mg ID: 652010

pump insulin amp diabetes insulin pump diabetes amp therapy csii type multiple group long mdi injections control 2015 glucose

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "To Pump OR To Inject" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

To Pump OR To Inject … that is the Question … ?

Sanoe

Harrison & Patrick HanleySlide2

Autoimmune Diabetes MellitusReview of ProblemSlide3

Glucose in Healthy Volunteers

Day

Ave ± SD = 93.0

±

7.0

mg/

dl, Night Ave ± SD = 81.8

± 6.3 mg/dl Slide4
Slide5
Slide6

DCCT

(Diabetes Control and Complication Trial)Slide7

Goals for long term health …A1c < 7.5Absence of severe hypoglycemiaMinimize glucose variability …Normal blood pressure

Normal cholesterol (LDL & HDL)

Normal weight (BMI

<85th percentile for age

& sex)Slide8

Insulin DiscoverySlide9

First glucometer 1968

First insulin syringe 1949Slide10

1963 - Dr. Arnold Kadish

designed the first insulin pump to be worn as a

backpackSlide11

Sanoe’s StorySlide12

Sanoe’s TimelineSlide13

Pat’s StorySlide14

Pat’s TimelineSlide15

Discussion Questions … What made you choose this breakout session?Who uses a pump for insulin?Who uses MDI for insulin?Slide16

Is there research to help us decide … ?We all know the first key is … taking our insulin and checking our blood sugar! But the question is …

with more options today to deliver insulin and monitor glucose is one way better?

Evidence based medicine but also need to consider

w

hat is best for you the individual patient/family? Slide17

Some Articles Comparing CSII to MDI“Long-term health economic benefits of sensor- augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a UK

perspective”

-

Journal of Medical Economics 2016

Continuous

subcutaneous insulin infusion therapy and multiple daily insulin injections in type 1 diabetes mellitus: a comparative overview and future

horizons”

-

Expert Opinion on Drug Delivery 2015

“Multiple

Daily Injections OR Insulin Pump Therapy:

Choosing the Best Option for Your Patient—An Evidence-based

Approach”

– Current Diabetes Reports 2015

“Does

treatment with an insulin pump improve

glycaemic

control in children and adolescents with type 1 diabetes? A retrospective case–control study”

- Pediatric Diabetes 2015 Slide18

Articles Comparing CSII to MDI“Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18,168 people with type 1 diabetes: observational study”

– British Medical Journal 2015

Insulin pump use in young children in the T1D Exchange clinic registry is associated with lower hemoglobin A1c levels than injection therapy

” - Pediatric Diabetes 2014

“Long

-term outcome of insulin pump therapy in children with type 1 diabetes assessed in a large population-based case–control

study”

Diabetologia

2013

A

randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin

glargine

– Diabetes Care 2004Slide19
Slide20
Slide21
Slide22
Slide23
Slide24
Slide25
Slide26

Major findings of this paper Showed that treatment with CSII resulted in an improvement in HbA1c levels up to 1 year (8.1% vs. 8.3%)

#

of severe

hypoglycaemic

events with

CSII

=

incidence rates of severe

hypoglycaemic

episodes per

100 person

-years were 3 in the CSII group & 6

in the MDI

group

Frequency of ketoacidosis

in CSII group

=

There were

2.8 episodes of

DKA/

100 person-

years

in the CSII group

&

0.5

in

the MDI group

insulin needed in CSII group & no change in weightSlide27

Why do some people stop using pumps?Main reasons found in one study:Greater sense of disease (93%)

Difficulties in doing sports (70%)

W

orse well

-being during pump therapy (63%

)

H

aving

to attach the pump to the body (60%

)

E

mbarrassment

(56%

)

A

dhesions &

pain in the place of needle insertion (50%

)

Difficulties

in controlling

glycemia

during physical

exercise (43%)

Fear

(43%

)

H

igh

levels of HbA1c (36%

)

Frequent

blood glucose monitoring (26%

)

“Reasons

for the discontinuation of therapy of personal insulin pump in children with type 1

diabetes”

Pediatr

Endocrinol

Diabetes

Metab

2015;21,2:65-69Slide28

Pros & Cons of PumpsProsFlexible basal rates Advanced bolus optionsConvenience of giving multiple dosesSlightly decreased total insulin needCons

Risk of DKA with pump malfunction

Hardware attached to body

CostSlide29

Pros & Cons of MDI ProsReliable absorptionNot connected to deviceMore affordable ConsCannot alternate basal rates

Multiple injections

Harder to disguise Slide30

Special Considerations

Image from:

http://

keralaeditor.com

/

kerala

-to-provide-free-insulin-pumps-for-diabetic-kids/Slide31

Case 118 y/o F, got a pump 2yrs ago, and is now going away to collegeAt school she is too busy to test sugar more than 2x per dayShe noticed that her pump insulin reservoir lasts her 5 daysShe usually gets home late, tests, changes her pump sites as needed right before going to bedSlide32

Case 214 year old boy on MDI since diagnosis 2 yrs agoNormally hyperglycemic in the morning despite changing lantus dose Hypoglycemia often with sports

Very active with sports & motivated to do better with his diabetes control

…Slide33

How do you define success with Diabetes?Slide34

Future Directions Slide35

Affreza – Inhaled InsulinSlide36

AbsorptionSlide37

Afrezza – Side EffectsRespiratoryDecreased Lung function in some (6 vs. 3%)Cough ~25 %Cancer

4 cases of lung cancer (2 smokers)Slide38

DegludecSlide39

DegludecPharmacokinetic properties: Long half-life (25 h)Long duration of action (42 h)Lower variability (25% that glarginie) from other basal analogues

Need studies in pediatric patients

… Slide40

A few more questions … Why did you choose your current therapy? Do you want to change?If so why?

Thank you very much for your attention & participation

… any

questions?